Evidence map›Paper›PMID 28039364›Full record

ReviewNeuro-oncology2017

Leptomeningeal metastases: a RANO proposal for response criteria.

Marc Chamberlain, Larry Junck, Dieta Brandsma, Riccardo Soffietti, Roberta Rudà, Jeffrey Raizer, Willem Boogerd, Sophie Taillibert, Morris D Groves, Emilie Le Rhun and 4 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06431685 (Phase I Study of Whole Brain Low Dose Radiotherapy Combined With ICI and Intrathecal Chemotherapy for Treatment of Refractory Meningeal Metastasis of Lung Cancer), which is not on this map. Cited by 219 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
219citing papers in PubMed, 6 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06431685 phase1recruitingnot on this mapstarted 2024, after this paper: background citation

Phase I Study of Whole Brain Low Dose Radiotherapy Combined With ICI and Intrathecal Chemotherapy for Treatment of Refractory Meningeal Metastasis of Lung Cancer

TypeinterventionalSponsorSichuan UniversityRan2024 to 2026Enrolled10ConditionsNSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal MetastasisArmsWhole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab, Chemotherapy
3 · Its place in the literature

Who cites it

219 citing papers in PubMed, 6 syntheses or guidelines pooled it, 315 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Article

159 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Marc ChamberlainDepartment of Neurology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA.
Larry JunckDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Dieta BrandsmaDepartment of Neuro-Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Riccardo SoffiettiDepartment of Neuro-Oncology, University Hospital, Torino, Italy.
Roberta RudàDepartment of Neuro-Oncology, University Hospital, Torino, Italy.
Jeffrey RaizerDepartment of Neurology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Willem BoogerdDepartment of Neuro-Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Sophie TaillibertDepartments of Neuro-Oncology Marazin and Radiation Oncology, Pitie-Salpetrieree Hospital and University Pierre et Marie Curie, Paris VI, Paris, France.
Morris D GrovesAustin Brain Tumor Center, Texas Oncology/US Oncology Research, Austin, Texas, USA.
Emilie Le RhunDepartment of Neuro-Oncology, University Hospital, Department of Neurology, Oscar Lambret Center, Lille, France.
Julie WalkerDepartment of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Martin van den BentDepartment of Neuro-oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.
Kurt A JaeckleDepartments of Neurology and Oncology, Mayo Clinic Florida, Jacksonville, Florida, USA.
The Netherlands Cancer Institute · NLDana-Farber Brigham Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.

Indexed as

Clinical Trials as TopicDisease ProgressionHumansMagnetic Resonance ImagingMeningeal NeoplasmsTreatment OutcomeCSF cytology/flow cytometryleptomeningeal metastasisneuraxis MRIneurological examination

Identifiers

PMID28039364
PMCPMC5464328
OpenAlexW2168394700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.